CAR-T-Cell Shows Promise in Patients With Lymphoma of the Brain and Spinal Cord in Early Trial

Axicabtagene ciloleucel (axi-cel), a form of CAR-T therapy appears to be safe and has encouraging signs of efficacy in treating both lymphoma of the brain and spinal cord injury.

Related Keywords

Boston ,Massachusetts ,United States ,Dana Farber Cancer Institute ,American ,Dana Farber Caron Jacobson ,James Kaminski ,Leslie Kean ,Dana Farber Ulrike Gerdemann ,Alexandre Albanese ,American Society Of Hematology ,Broad Institute ,Dana Faber Cancer Institute ,Systems Immunology Lab ,Dana Faber Cancer ,American Society ,Cellular Therapeutics ,Boston Children ,Caron Jacobson ,Ulrike Gerdemann ,Press Office ,Neuroscience Newsletter ,